Invest in the weight loss drug revolution and beyond
$HRTS ETF
Learn more

CANC
Oncology ETF

Investing behind the prevention and cure of cancer

Why CANC ETF?

icons-themes-oncology-impact
Impact

Investors can provide capital to companies pioneering cures and early detection of cancer

icons-themes-oncology-innovation
Innovation

The life sciences industry is still in the early stages of a revolution in oncology innovations - from CAR-T cell therapies to bi-specific antibodies - powered by biological insights and growing capabilities

icons-themes-oncology-platforms
Research Expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations

icons-themes-oncology-growth
Growth

Oncology is an increasingly prioritized therapeutic class with treatment spend expected to grow substantially, driven by an aging population; this secular growth trend also tends to be insulated from economic cycles

icons-themes-oncology-uncorrelated
Uncorrelated

Performance of many biotechnology companies relies on clinical success which is an uncorrelated source of return

Fund Overview

Fund Details

As of June 18, 2024
Primary Exchange
Nasdaq
Ticker
CANC
AuM (USD)
$28,805,339
# of Holdings
50
Fund Inception Date
08/14/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
1,327,275
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$36M
Shares Outstanding
1,070,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/30/2025

Fund Summary

The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals. The growing complexity of scientific discovery, regulation and a surge in investment opportunities requires expertise to navigate this exciting chapter in human development.

Portfolio Manager

David K. Song, MD, PhD, CFA
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.

How does the Tema CANC ETF fit in a portfolio?

Investment Style Box

Frame 48095809

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM
Ellipse 625

CANC ETF

Ellipse 625

Equity core

Where could a position be funded from?

  • Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.

  • Provides a balanced exposure across key oncology areas and company risk profiles.

  • Could replace a satellite or a growth-oriented position.

Portfolio Breakdown

Top 10 holdings

As of June 18, 2024
Company
% of Nav
REGENERON PHARMACEUTICALS, INC.
5.94%
ASTRAZENECA PLC
5.63%
MERCK & CO., INC.
4.81%
INTELLIA THERAPEUTICS, INC.
3.78%
DAIICHI SANKYO CO., LTD.
3.75%
AMGEN, INC.
3.33%
MEREO BIOPHARMA GROUP PLC
3.32%
INCYTE CORP.
3.20%
EXELIXIS, INC.
3.08%
ILLUMINA, INC.
2.99%

Country Breakdown

United States
66.89%
United Kingdom
9.72%
Japan
6.26%
Switzerland
5.36%
Others
11.77%

Industry Breakdown

Healthcare
98.92%
Cash & Cash Equivalents
1.07%
  • Performance
  • Distributions
  • Premium / Discount

Prices & Performance

As of
May 31, 2024

CANC

3 months

1 Year

3 Years

5 Years

Since inception

NAV
-5.42% 6.39%
6.72% 12.27%
Market Price
-5.17% 6.52%
7.11% 12.59%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.


The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

Dec 14, 2023
Dec 13, 2023
Dec 15, 2023
$0.149112
$0.134232
$0.014880
0.55 0.31 0.19 0.38 0.68 -0.03 0.06 0.41 0.3 0.28 -0.06 0.2

Premium/Discount

Сhart Table

CANC NAV / Market Price

NAV$26.92
NAV change (1D)($0.21)
Median Bid/Ask Spread (30 Day)0.58%
Market Price$27.07
Market Price Change (1D)($0.14)
Premium/Discount0.55%
As of: June 18, 2024

How to buy

*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.